Paroxysmal nocturnal hemoglobinuria. A complement-mediated disease - PubMed (original) (raw)
Review
Paroxysmal nocturnal hemoglobinuria. A complement-mediated disease
J A Halperin et al. Complement Inflamm. 1989.
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a hemolytic disease characterized by an increased sensitivity of erythrocytes to the hemolytic action of complement. Two membrane proteins, the decay-accelerating factor and the C8-binding protein, which protect normal erythrocytes from the hemolytic action of complement, are deficient on the abnormal blood cells from patients with PNH. Other membrane proteins unrelated to complement regulation, but which share with the decay-accelerating factor and the C8-binding protein a common post-translational modification, namely a glycan-phosphatidylinositol linkage to the cell membrane, are also missing from PNH cells. In the present review, clinical, biological, and molecular aspects of PNH are discussed. In addition, diagnostic tests in clinical use are discussed, and new tests using indirect immunofluorescent assays are proposed.
Similar articles
- Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
Medof ME, Gottlieb A, Kinoshita T, Hall S, Silber R, Nussenzweig V, Rosse WF. Medof ME, et al. J Clin Invest. 1987 Jul;80(1):165-74. doi: 10.1172/JCI113043. J Clin Invest. 1987. PMID: 2439544 Free PMC article. - [Paroxysmal nocturnal hemoglobinuria].
Blaas P, Weber S, Hänsch GM, Peter HH. Blaas P, et al. Klin Wochenschr. 1990 Mar 5;68(5):247-55. doi: 10.1007/BF02116052. Klin Wochenschr. 1990. PMID: 2182938 Review. German. - Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM. Risitano AM. Adv Exp Med Biol. 2013;735:155-72. doi: 10.1007/978-1-4614-4118-2_10. Adv Exp Med Biol. 2013. PMID: 23402025 Review. - Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
Parker CJ, Wiedmer T, Sims PJ, Rosse WF. Parker CJ, et al. J Clin Invest. 1985 Jun;75(6):2074-84. doi: 10.1172/JCI111927. J Clin Invest. 1985. PMID: 4008653 Free PMC article.
Cited by
- Role of complement and complement regulatory proteins in the complications of diabetes.
Ghosh P, Sahoo R, Vaidya A, Chorev M, Halperin JA. Ghosh P, et al. Endocr Rev. 2015 Jun;36(3):272-88. doi: 10.1210/er.2014-1099. Epub 2015 Apr 10. Endocr Rev. 2015. PMID: 25859860 Free PMC article. Review. - Molecular basis for a link between complement and the vascular complications of diabetes.
Acosta J, Hettinga J, Flückiger R, Krumrei N, Goldfine A, Angarita L, Halperin J. Acosta J, et al. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5450-5. doi: 10.1073/pnas.97.10.5450. Proc Natl Acad Sci U S A. 2000. PMID: 10805801 Free PMC article. - Ca2+-activated K+ efflux limits complement-mediated lysis of human erythrocytes.
Halperin JA, Brugnara C, Nicholson-Weller A. Halperin JA, et al. J Clin Invest. 1989 May;83(5):1466-71. doi: 10.1172/JCI114039. J Clin Invest. 1989. PMID: 2708520 Free PMC article. - Isolation and characterization of a membrane-attack-complex-inhibiting protein present in human serum and other biological fluids.
Watts MJ, Dankert JR, Morgan EP. Watts MJ, et al. Biochem J. 1990 Jan 15;265(2):471-7. doi: 10.1042/bj2650471. Biochem J. 1990. PMID: 2302178 Free PMC article.